IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience

Area of Science:

• Oncology
• Genetics
• Skeletal Tumors

Background:

• Isocitrate dehydrogenase (IDH) mutations are prevalent in conventional central bone chondrosarcomas (CCBC).
• Understanding the frequency and prognostic significance of IDH mutations in high-grade CCBC is crucial.

Purpose of the Study:

• To determine the frequency of IDH mutations in high-grade CCBC.
• To evaluate the prognostic impact of IDH mutations on patient survival and recurrence in CCBC.

Main Methods:

• Analysis of 64 patients with Grade 2 (G2) and Grade 3 (G3) CCBC.
• DNA extraction, PCR amplification of IDH1/2 exon 4, and Sanger sequencing were performed to detect IDH mutations.

Main Results:

• IDH mutations were found in 44% of patients (24/54), with a higher frequency in G3 (69%) compared to G2 (37%) CCBC.
• No significant differences in overall survival (OS), relapse-free survival (RFS), or progression-free survival (PFS) were observed between IDH-mutated and IDH wild-type CCBC.
• Patients with IDH-mutated G2 CCBC showed a higher rate of progression to G3 at recurrence (55%) compared to IDH wild-type G2 CCBC (25%).

Conclusions:

• IDH mutations are more common in high-grade (G3) CCBC than in lower-grade (G2) tumors.
• IDH mutational status does not significantly affect OS, RFS, or PFS in CCBC patients.
• IDH-mutated CCBC, particularly at G2, demonstrates a propensity for higher-grade transformation upon recurrence.